Orphenadrine (BioDeep_00000002112)

 

Secondary id: BioDeep_00001867889

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine

化学式: C18H23NO (269.178)
中文名称: 邻甲苯海明
谱图信息: 最多检出来源 Homo sapiens(blood) 36.36%

分子结构信息

SMILES: CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
InChI: InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3

描述信息

Orphenadrine is only found in individuals that have used or taken this drug. It is a muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem]Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065686 - Cytochrome P-450 CYP2B6 Inhibitors
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents
C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3276

同义名列表

41 个代谢物同义名

N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine; N,N-Dimethyl-2-[(O-methyl-α-phenylbenzyl)oxy]ethylamine; N,N-Dimethyl-2-[(O-methyl-a-phenylbenzyl)oxy]ethylamine; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-Dimethyl-2-(phenyl(O-tolyl)methoxy)ethanamine; Dimethyl-[2-(phenyl-O-tolyl-methoxy)-ethyl]-amine; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; N,N-Dimethyl-2-(a-2-tolylbenzoyloxy)ethylamine; N,N-Dimethyl-2-(α-2-tolylbenzoyloxy)ethylamine; b-Dimethylaminoethyl 2-methylbenzhydryl ether; Β-dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-O-tolylmethyl dimethyaminoethyl ether; 2-(Phenyl-O-tolylmethoxy)ethyldimethylamine; Citrate, norflex orphenadrine; Orphenadrine citrate, norflex; Norflex orphenadrine citrate; Hydrochloride, orphenadrine; O-Monomethyldiphenhydramine; Orphenadrine hydrochloride; O-Methyldiphenhydramine; 2-Methyldiphenhydramine; Methyldiphenylhydramine; Citrate, orphenadrine; Orphenadrine citrate; Mefenamine, sodium; Sodium mefenamine; Orphenadrinum; Orphenedrine; orphenadrine; Orphenadrin; Orfenadrina; Orphenadine; Mephenamine; Mefenamine; Orphenate; Lysantin; Mialgin; Disipal; Norflex; Orphenadrine



数据库引用编号

26 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 13 CCND1, CYP1A1, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, GPX2, GSTM3, HPGDS, SLC6A3
Peripheral membrane protein 5 ACHE, CYP1A1, CYP1B1, CYP2B6, CYP2E1
Endoplasmic reticulum membrane 10 CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4
Nucleus 3 ACHE, CCND1, GSTM3
cytosol 4 CCND1, GPX2, GSTM3, HPGDS
centrosome 1 CCND1
nucleoplasm 3 CCND1, HPGDS, SCNN1G
Cell membrane 4 ACHE, SCN10A, SCN11A, SLC6A3
Cell projection, axon 1 SLC6A3
Multi-pass membrane protein 4 SCN10A, SCN11A, SCNN1G, SLC6A3
Synapse 1 ACHE
cell surface 2 ACHE, SLC6A3
glutamatergic synapse 1 SCN10A
Golgi apparatus 1 ACHE
mitochondrial inner membrane 2 CYP1A1, CYP2E1
neuromuscular junction 1 ACHE
neuronal cell body 2 SCN11A, SLC6A3
presynaptic membrane 2 SCN10A, SLC6A3
Cytoplasm, cytosol 1 GPX2
plasma membrane 7 ACHE, CYP2C19, CYP2C9, SCN10A, SCN11A, SCNN1G, SLC6A3
Membrane 7 ACHE, CYP1B1, CYP2A6, CYP2D6, CYP3A4, SCN11A, SLC6A3
apical plasma membrane 1 SCNN1G
axon 3 SCN10A, SCN11A, SLC6A3
extracellular exosome 4 GSTM3, SCN10A, SCN11A, SCNN1G
endoplasmic reticulum 1 CYP2D6
extracellular space 1 ACHE
perinuclear region of cytoplasm 1 ACHE
bicellular tight junction 1 CCND1
mitochondrion 3 CYP1A1, CYP1B1, CYP2D6
intracellular membrane-bounded organelle 11 CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, HPGDS
Microsome membrane 8 CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C9, CYP2D6, CYP2E1, CYP3A4
Secreted 1 ACHE
extracellular region 1 ACHE
Single-pass membrane protein 1 CYP2D6
neuronal cell body membrane 1 SLC6A3
Extracellular side 1 ACHE
Nucleus membrane 1 CCND1
nuclear membrane 1 CCND1
external side of plasma membrane 1 SCNN1G
postsynaptic membrane 1 SLC6A3
Apical cell membrane 1 SCNN1G
Mitochondrion inner membrane 2 CYP1A1, CYP2E1
Membrane raft 1 SLC6A3
flotillin complex 1 SLC6A3
basement membrane 1 ACHE
Cell projection, neuron projection 1 SLC6A3
neuron projection 1 SLC6A3
axonal growth cone 1 SCN11A
mitotic spindle 1 GPX2
Lipid-anchor, GPI-anchor 1 ACHE
intercellular bridge 2 GPX2, GSTM3
sodium channel complex 1 SCNN1G
side of membrane 1 ACHE
transcription repressor complex 1 CCND1
axon terminus 1 SLC6A3
cytoplasmic microtubule 1 CYP2A6
synaptic cleft 1 ACHE
dopaminergic synapse 1 SLC6A3
voltage-gated sodium channel complex 2 SCN10A, SCN11A
sperm fibrous sheath 1 GSTM3
cyclin-dependent protein kinase holoenzyme complex 1 CCND1
clathrin complex 1 SCN10A
cyclin D1-CDK4 complex 1 CCND1
[Isoform H]: Cell membrane 1 ACHE
cyclin D1-CDK6 complex 1 CCND1
C-fiber 1 SCN11A


文献列表

  • Anna Detzlhofer, Christian Grechhamer, Lawrence Madikizela, Markus Himmelsbach, Franz Mlynek, Wolfgang Buchberger, Christian W Klampfl. Uptake, translocation, and metabolization of amitriptyline, lidocaine, orphenadrine, and tramadol by cress and pea. Environmental science and pollution research international. 2024 Mar; 31(13):19649-19657. doi: 10.1007/s11356-024-32379-x. [PMID: 38363510]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Kit Yee Cheah, Kar Yee Mah, Lai Hui Pang, Shi Min Ng, Jia Woei Wong, Siew Siew Tan, Hong Zhe Tan, Kah Hay Yuen. A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition. BMC pharmacology & toxicology. 2020 06; 21(1):45. doi: 10.1186/s40360-020-00416-3. [PMID: 32576287]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Jessica L Knittel, Shawn P Vorce, Barry Levine, Rhome L Hughes, Thomas Z Bosy. Multidrug toxicity involving sumatriptan. Journal of analytical toxicology. 2015 Jan; 39(1):75-9. doi: 10.1093/jat/bku120. [PMID: 25324526]
  • Iu I Hubs'kyĭ, T A Bukhtiarova, H H Horiushko, N V Litvinova, H I Paramonova, T M Kurapova, O M Velychko, L P Babenko. [Biophysical parameters of erythrocyte membranes and mechanisms of interaction with non-opioid analgesics under acute pain syndrome]. Ukrainian biochemical journal. 2014 May; 86(3):98-106. doi: ". [PMID: 25033559]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Laia Tolosa, Sandra Pinto, M Teresa Donato, Agustín Lahoz, José V Castell, J Enrique O'Connor, M José Gómez-Lechón. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicological sciences : an official journal of the Society of Toxicology. 2012 May; 127(1):187-98. doi: 10.1093/toxsci/kfs083. [PMID: 22331495]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • M A Saracino, C Petio, M Vitali, L Franchini, M A Raggi. Determination of orphenadrine plasma levels using HPLC with diode array detection and a novel solid-phase extraction procedure in psychiatric patients. Journal of pharmaceutical and biomedical analysis. 2009 Oct; 50(3):501-6. doi: 10.1016/j.jpba.2009.05.010. [PMID: 19524386]
  • Mirosław Czuczwar, Jacek Cieszczyk, Katarzyna Czuczwar, Jacek Kiś, Tomasz Saran, Waldemar A Turski. Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice. Pharmacological reports : PR. 2009 Jul; 61(4):732-6. doi: 10.1016/s1734-1140(09)70127-6. [PMID: 19815957]
  • M Elghazali, I A Wasfi, A A Abdel Hadi, A M Latum. Pharmacokinetic, metabolism and withdrawal time of orphenadrine in camels (Camelus dromedarius) after intravenous administration. Research in veterinary science. 2008 Dec; 85(3):563-9. doi: 10.1016/j.rvsc.2008.01.006. [PMID: 18321539]
  • María Amparo Martínez-Gómez, Rosa María Villanueva-Camañas, Salvador Sagrado, Maria José Medina-Hernández. Evaluation of enantioselective binding of basic drugs to plasma by ACE. Electrophoresis. 2007 Aug; 28(17):3056-63. doi: 10.1002/elps.200700222. [PMID: 17661317]
  • María Amparo Martínez-Gómez, Rosa M Villanueva-Camañas, Salvador Sagrado, María José Medina-Hernández. Evaluation of enantioselective binding of antihistamines to human serum albumin by ACE. Electrophoresis. 2007 Aug; 28(15):2635-43. doi: 10.1002/elps.200600742. [PMID: 17605150]
  • Mei-juan Xu, Guang-ji Wang, Hai-tang Xie, Qing Huang, Yuan-wei Jia. [Enzyme kinetics of schizandrin metabolism and sex differences in rat liver microsomes]. Yao xue xue bao = Acta pharmaceutica Sinica. 2007 Jul; 42(7):730-4. doi: . [PMID: 17882956]
  • M A Martínez-Gómez, S Sagrado, R M Villanueva-Camañas, M J Medina-Hernández. Enantiomeric quality control of antihistamines in pharmaceuticals by affinity electrokinetic chromatography with human serum albumin as chiral selector. Analytica chimica acta. 2007 Jun; 592(2):202-9. doi: 10.1016/j.aca.2007.04.029. [PMID: 17512827]
  • M A Martínez-Gómez, M M Carril-Avilés, S Sagrado, R M Villanueva-Camañas, M J Medina-Hernández. Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. Journal of chromatography. A. 2007 Apr; 1147(2):261-9. doi: 10.1016/j.chroma.2007.02.054. [PMID: 17339039]
  • Soo-Youn Lee, Hyeon Ju Oh, Jong Won Kim, Yoon Gyoon Kim, Chul Jin Moon, Eun Hee Lee. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Jul; 839(1-2):118-23. doi: 10.1016/j.jchromb.2006.02.056. [PMID: 16580894]
  • Chika Hasegawa, Takeshi Kumazawa, Xiao-Pen Lee, Masaya Fujishiro, Ayako Kuriki, Akemi Marumo, Hiroshi Seno, Keizo Sato. Simultaneous determination of ten antihistamine drugs in human plasma using pipette tip solid-phase extraction and gas chromatography/mass spectrometry. Rapid communications in mass spectrometry : RCM. 2006; 20(4):537-43. doi: 10.1002/rcm.2335. [PMID: 16419026]
  • Shigeru Furuta, Emiko Kamada, Takeshi Omata, Tohru Sugimoto, Yoshihiro Kawabata, Keiko Yonezawa, Xiaochun Cheryl Wu, Tadashi Kurimoto. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. European journal of pharmacology. 2004 Aug; 497(2):223-31. doi: 10.1016/j.ejphar.2004.06.040. [PMID: 15306208]
  • Teemu Gunnar, Sirpa Mykkänen, Kari Ariniemi, Pirjo Lillsunde. Validated semiquantitative/quantitative screening of 51 drugs in whole blood as silylated derivatives by gas chromatography-selected ion monitoring mass spectrometry and gas chromatography electron capture detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Jul; 806(2):205-19. doi: 10.1016/j.jchromb.2004.04.005. [PMID: 15171931]
  • Pekka Suomalainen, Christoffer Johans, Tim Söderlund, Paavo K J Kinnunen. Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. Journal of medicinal chemistry. 2004 Mar; 47(7):1783-8. doi: 10.1021/jm0309001. [PMID: 15027870]
  • S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville, T Fischer. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer. 2003 Nov; 89(10):1855-9. doi: 10.1038/sj.bjc.6601152. [PMID: 14612892]
  • Youssef Hijazi, Roselyne Boulieu. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2002 Jul; 30(7):853-8. doi: 10.1124/dmd.30.7.853. [PMID: 12065445]
  • N Fucci, B Romano, A Zirilli. Acute intoxication with orphenadrine and clozapine. Forensic science international. 2001 Nov; 123(1):13-6. doi: 10.1016/s0379-0738(01)00509-6. [PMID: 11731191]
  • I Van Herreweghe, K Mertens, V Maes, J Ramet. Orphenadrine poisoning in a child: clinical and analytical data. Intensive care medicine. 1999 Oct; 25(10):1134-6. doi: 10.1007/s001340051024. [PMID: 10551971]
  • E G Brain, L J Yu, K Gustafsson, P Drewes, D J Waxman. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. British journal of cancer. 1998 Jun; 77(11):1768-76. doi: 10.1038/bjc.1998.295. [PMID: 9667645]
  • D Hannak, F Scharbert, R Kattermann. Stepwise binary gradient high-performance liquid chromatographic system for routine drug monitoring. Journal of chromatography. A. 1996 Mar; 728(1-2):307-10. doi: 10.1016/0021-9673(95)01169-2. [PMID: 8673233]
  • M Contin, R Riva, P Martinelli, G Procaccianti, F Albani, A Baruzzi. Combined levodopa-anticholinergic therapy in the treatment of Parkinson's disease. Effect on levodopa bioavailability. Clinical neuropharmacology. 1991 Apr; 14(2):148-55. doi: 10.1097/00002826-199104000-00004. [PMID: 2015611]
  • A C Altamura, M C Mauri, F De Novellis, M Percudani, V Vampini. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine. Pharmacopsychiatry. 1989 Nov; 22(6):246-9. doi: 10.1055/s-2007-1014608. [PMID: 2616635]
  • J M Treherne, J M Young. [3H]-(+)-N-methyl-4-methyldiphenhydramine, a quaternary radioligand for the histamine H1-receptor. British journal of pharmacology. 1988 Jul; 94(3):797-810. doi: 10.1111/j.1476-5381.1988.tb11591.x. [PMID: 3179613]
  • M Contin, R Riva, F Albani, A Baruzzi. Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomedical chromatography : BMC. 1987; 2(5):193-4. doi: 10.1002/bmc.1130020504. [PMID: 3507235]
  • G T Blyden, D J Greenblatt, J M Scavone, R I Shader. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. Journal of clinical pharmacology. 1986 Sep; 26(7):529-33. doi: 10.1002/j.1552-4604.1986.tb02946.x. [PMID: 3760245]
  • A C Altamura, M Buccio, F Colacurcio, G Colombo, A Terzi. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta neurologica. 1986 Feb; 8(1):19-26. doi: NULL. [PMID: 3962752]
  • A C Altamura, M Buccio, G Colombo, A Terzi, C L Cazzullo. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study. L'Encephale. 1986 Jan; 12(1):31-6. doi: . [PMID: 3698889]
  • M Furlanut, D Bettio, I Bertin, G Colombo, P Benetello. Orphenadrine serum levels in a poisoned patient. Human toxicology. 1985 May; 4(3):331-3. doi: 10.1177/096032718500400316. [PMID: 4007897]
  • A Bast, E M Savenije-Chapel, J Noordhoek. Relationship between molecular structure and cytochrome P450-metabolic intermediate complex formation, studied with orphenadrine analogues. Journal of pharmaceutical sciences. 1984 Jul; 73(7):953-6. doi: 10.1002/jps.2600730723. [PMID: 6470960]
  • R C Meatherall, D R Guay. Isothermal gas chromatographic analysis of diphenhydramine after direct injection onto a fused-silica capillary column. Journal of chromatography. 1984 May; 307(2):295-304. doi: 10.1016/s0378-4347(00)84101-8. [PMID: 6736178]
  • D Lutz, W Gielsdorf, H Jaeger. Quantitative determination of diphenhydramine and orphenadrine in human serum by capillary gas chromatography. Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie. 1983 Oct; 21(10):595-7. doi: 10.1515/cclm.1983.21.10.595. [PMID: 6644246]
  • L F Wilkinson, B M Thomson, L K Pannell. A report on the analysis of orphenadrine in post mortem specimens. Journal of analytical toxicology. 1983 Mar; 7(2):72-5. doi: 10.1093/jat/7.2.72. [PMID: 6855206]
  • L I Harrison, C R Kehe, M B Goldlust, D C Kvam, J R Bianchine. Salicylic acid plasma levels following multiple doses of Norgesic Forte and aspirin. Therapeutic drug monitoring. 1983; 5(4):401-4. doi: 10.1097/00007691-198312000-00004. [PMID: 6689225]
  • G Rutigliano, J J Labout. The bioavailability of orphenadrine hydrochloride after intramuscular and oral administration. The Journal of international medical research. 1982; 10(6):447-50. doi: 10.1177/030006058201000612. [PMID: 7152086]
  • J J Labout, C t Thijssen, G G Keijser, W Hespe. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. European journal of clinical pharmacology. 1982; 21(4):343-50. doi: 10.1007/bf00637624. [PMID: 7056281]
  • G B Burnett, A J Prange, I C Wilson, L A Jolliff, I C Creese, S H Synder. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology. 1980; 6(2):109-20. doi: 10.1159/000117742. [PMID: 6101910]
  • J Huisman, L L Liebregt, J H Thyssen. Gas chromatographic determination of (o-methyl-alpha-phenylbenzyloxy)acetic acid levels in human serum following therapeutic doses of orphenadrin (Disipal). Journal of chromatography. 1979 Dec; 164(4):510-4. doi: 10.1016/s0378-4347(00)81555-8. [PMID: 541428]
  • L B Hansen, J Elley, T R Christensen, N E Larsen, J Naestoft, E F Hvidberg. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. British journal of clinical pharmacology. 1979 Jan; 7(1):75-80. doi: 10.1111/j.1365-2125.1979.tb00900.x. [PMID: 760745]
  • P M Cotes, T J Crow, E C Johnstone, W Bartlett, R C Bourne. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychological medicine. 1978 Nov; 8(4):657-65. doi: 10.1017/s0033291700018869. [PMID: 364517]
  • J J Labout, C T Thijssen, W Hespe. Sensitive and specific gas chromatographic and extraction method for the determination of orphenadrine in human body fluids. Journal of chromatography. 1977 Dec; 144(2):201-8. doi: 10.1016/s0021-9673(00)99355-5. [PMID: 925110]
  • W M Wiersinga, A J Fabius, J L Touber. Orphenadrine (Disipal), serum thyroxine and thyroid function. Acta endocrinologica. 1977 Nov; 86(3):522-32. doi: 10.1530/acta.0.0860522. [PMID: 72472]
  • A E Robinson, A T Holder, R D McDowall, R Powell, H Sattar. Forensic toxicology of some orphenadrine-related deaths. Forensic science. 1977 Jan; 9(1):53-62. doi: 10.1016/0300-9432(77)90067-x. [PMID: 838418]
  • G Mendelson. Letter: Hallucinogenic plants. The Medical journal of Australia. 1975 Jun; 1(26):839. doi: ". [PMID: 1152781]
  • S Loga, S Curry, M Lader. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British journal of clinical pharmacology. 1975 Jun; 2(3):197-208. doi: 10.1111/j.1365-2125.1975.tb01576.x. [PMID: 791320]
  • J U Postma, W Van Tilburg. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). Journal of the American Geriatrics Society. 1975 May; 23(5):212-5. doi: 10.1111/j.1532-5415.1975.tb00187.x. [PMID: 123540]
  • D G Gill, H A Sowerby. Orphenadrine poisoning in childhood. The Practitioner. 1975 Apr; 214(1282):542-544. doi: NULL. [PMID: 1144265]
  • M H Lader. [Rational utilization of the major tranquilizers]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952). 1975; 75(9):1401-5. doi: NULL. [PMID: 241182]
  • D A Bender, A N Bamji. Serum tryptophan binding in chlorpromazine-treated chronic schizophrenics. Journal of neurochemistry. 1974 May; 22(5):805-9. doi: 10.1111/j.1471-4159.1974.tb04298.x. [PMID: 4407100]
  • P R Andersen, P Gibbs, H Kubinski. Effects of neuropharmacological agents on in vitro formation of complexes between nucleic acids and proteins. Neuropharmacology. 1974 Feb; 13(2):111-7. doi: 10.1016/0028-3908(74)90028-8. [PMID: 4595677]
  • W Bilzer, U Gundert-Remy. Determination of nanogram quantities of diphenhydramine and orphenadrine in human plasma using gas-liquid chromatography. European journal of clinical pharmacology. 1973 Dec; 6(4):268-70. doi: 10.1007/bf00644744. [PMID: 4777260]
  • T Ellison. Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey. Archives internationales de pharmacodynamie et de therapie. 1972 Feb; 195(2):213-30. doi: NULL. [PMID: 4622666]
  • A H Beckett, F Khan. Metabolism, distribution and excretion of orphenadrine in man. The Journal of pharmacy and pharmacology. 1971 Dec; 23(?):222S. doi: 10.1111/j.2042-7158.1971.tb08802.x. [PMID: 4401471]
  • T Ellison, A Snyder, J Bolger, R Okun. Metabolism of orphenadrine citrate in man. The Journal of pharmacology and experimental therapeutics. 1971 Feb; 176(2):284-95. doi: NULL. [PMID: 5568779]
  • H Prins, W Hespe. Autoradiographic study of the distribution of radioactivity in mice after oral administration of tritium-labelled orphenadrine hydrochloride. Archives internationales de pharmacodynamie et de therapie. 1968 Jan; 171(1):47-57. doi: NULL. [PMID: 5646024]
  • W Hespe, W F Kafoe, W T Nauta. Evidence for side-chain degradation of orphenadrine HCl in the rat. Biochemical pharmacology. 1967 Sep; 16(9):1847-8. doi: 10.1016/0006-2952(67)90262-6. [PMID: 6053225]
  • L R Gjessing. Effect of thyroxine, pyridoxine, orphenadrine-HCl, resperine and disulfiram in periodic catatonia. Acta psychiatrica Scandinavica. 1967; 43(4):376-84. doi: 10.1111/j.1600-0447.1967.tb05775.x. [PMID: 5582389]
  • J Johnson, G Milner. Psychiatric complications of amphetamine substances. Acta psychiatrica Scandinavica. 1966; 42(3):252-63. doi: 10.1111/j.1600-0447.1966.tb01930.x. [PMID: 5959089]
  • A HERZ, H TESCHEMACHER, A HOFSTETTER, H KURZ. THE IMPORTANCE OF LIPID-SOLUBILITY FOR THE CENTRAL ACTION OF CHOLINOLYTIC DRUGS. International journal of neuropharmacology. 1965 Jul; 4(?):207-18. doi: 10.1016/0028-3908(65)90037-7. [PMID: 14343875]
  • W Hespe, A M de Roos, W T Nauta. Investigation into the metabolic fate of orphenadrine hydrochloride after oral administration to male rats. Archives internationales de pharmacodynamie et de therapie. 1965 Jul; 156(1):180-200. doi: NULL. [PMID: 5858833]
  • VAN DEENENL, R A DEMEL. PENETRATION OF LIPID MONOLAYERS BY PSYCHOACTIVE DRUGS. Biochimica et biophysica acta. 1965 Jan; 94(?):314-6. doi: 10.1016/0926-6585(65)90039-7. [PMID: 14273414]